













This is the peer reviewed version of the following article:  
Menopausal hormone therapy and the risk of 
esophageal and gastric cancer, which has been published 




This article may be used for non-commercial purposes in 





























































































































































































































































































































































































































































































































































		 Number	(%)	 Number	(%)	 OR	(95%	CI)*	 Number	(%)	 OR	(95%	CI)*	 Number	(%)	 OR	(95%	CI)*	
Esophageal	
adenocarcinoma	 224	(0.03)	 46	(0.02)	 0.62	(0.45-0.85)	 24	(0.02)	 0.57	(0.37-0.87)	 22	(0.01)	 0.70	(0.45-1.09)	
Gastric	
adenocarcinoma	 608	(0.07)	 123	(0.04)	 0.61	(0.50-0.74)	 75	(0.06)	 0.60	(0.47-0.76)	 48	(0.03)	 0.64	(0.48-0.87)	
Esophageal	squamous	














Esophageal	adenocarcinoma		 	 	 	
<60	years	 3	(0.00)	 43	(0.01)	 0.20	(0.06-0.65)	
60-69	years	 14	(0.01)	 67	(0.03)	 0.60	(0.34-1.07)	
≥70	years	 29	(0.03)	 14	(0.00)	 0.79	(0.52-1.19)	
Gastric	adenocarcinoma	 	 	 	
<60	years	 12	(0.01)	 89	(0.03)	 0.39	(0.21-0.71)	
60-69	years	 37	(0.04)	 153	(0.06)	 0.69	(0.48-0.98)	
≥70	years	 74	(0.08)	 366	(0.13)	 0.63	(0.49-0.81)	
Esophageal	squamous	cell	carcinoma		 	 	 	
<60	years	 4	(0.00)	 14	(0.00)	 0.80	(0.26-2.44)	
60-69	years	 9	(0.00)	 63	(0.02)	 0.41	(0.20-0.82)	
≥70	years	 20	(0.02)	 97	(0.04)	 0.65	(0.40-1.05)	
	
*Adjusted	for	age,	parity,	hysterectomy,	thrombotic	events,	diabetes	mellitus,	obesity,	smoking-related	diseases,	alcohol-related	diseases,	and	
osteoporosis	(all	but	osteoporosis	were	used	for	matching	
